What Arecor does
Arecor Limited is a privately-owned biopharmaceuticals company developing superior diabetes care through the application of its innovative formulation technology platform.
Arecor is leveraging this platform to:
(i) develop a portfolio of proprietary products for diabetes care
(ii) deliver superior reformulations of its partners proprietary products.
It partners with major pharma and biotech companies to develop improved versions of their key products, as well as developing its own products.
In October, Arecor Limited signed a research, development and commercialisation agreement with JDRF, the world's leading type 1 diabetes research charity.
Under the collaboration, Arecor and JDRF will invest equal funds to develop AT271, a liquid combination of insulin and pramlintide, which is used to replace a hormone absent in people with type 1 diabetes.
The company said it had demonstrated the combined injection of these two drugs at mealtimes helps with controlling the blood sugar level, losing weight and reducing insulin doses.
It noted that pramlintide is currently “underutilised” because there is no combined injectable solution containing insulin and patients need to carry out separate injections.
Arecor will use its proprietary formulation technology platform, Arestat to develop a new, co-formulation of pramlintide and insulin.
Elsewhere, the company also finished dosing and patient visits in the Austria-based phase I of its ultra-rapid acting insulin candidate, AT247, with results expected by the end of the year.
The product is designed to improve treatment for people living with Type I diabetes, by accelerating insulin absorption to manage more effectively blood glucose levels, especially after meals.
Watch the interview
What the boss says
Chief executive Dr Sarah Howell said that diabetes has hit “epidemic proportions” with 425mln sufferers worldwide.
Howell noted: “There’s still an unmet need for these faster-acting insulins that are really more like a physicological insulin, so match a healthy person’s response to spikes in blood glucose.”
“Really now the focus is on progressing all of our assets and all of our products into clinical stages and proving the clinical benefits and healthcare outcomes," she added.